University of Groningen
A geriatric perspective on chronic kidney disease
Bos, Harmke Anthonia
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Bos, H. A. (2019). A geriatric perspective on chronic kidney disease: The three M's. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Chapter 3
Low urinary Creatinine Excretion
is associated with Self-Reported
Frailty in Patients with Advanced
Chronic Kidney Disease
Harmke A. Polinder-Bos1
Hakan Nacak2
Friedo W. Dekker2
Stephan J.L. Bakker1
Carlo A.J.M. Gaillard1
Ron T. Gansevoort1
1Division of Nephrology, Department of Internal Medicine, University Medical
Center Groningen, University of Groningen, Groningen, the Netherlands.
2Department of Clinical Epidemiology, Leiden University Medical Center,
Leiden, The Netherlands.
ABSTRACT Introduction
Frailty and muscle wasting, a component of frailty, are common in advanced stage chronic kidney disease (CKD). Whether frailty is associated with a low urinary creatinine excretion (UCrE) as a measure of muscle mass in this population is unknown. Further-more, reference values of UCrE are lacking. We first defined low UCrE and studied cor-relates of low UCrE, and subsequently studied cross-sectional associations of frailty with low UCrE in patients with advanced CKD.
Methods
A total of 2748 healthy individuals of the general population-based PREVEND study were included to define low UCrE (UCrE indexed for height, below the age- and sex-specific 5th percentile of the distribution). Frailty was defined using a modification of the Fried frailty phenotype. In a CKD population that included 320 and 967 participants of the PREPARE-2 and NECOSAD studies, respectively, cross-sectional associations of self-reported frailty, the individual components that define self-reported frailty, and frailty-associated variables with low UCrE were evaluated using multivariate logistic and linear regression models.
Results
Low UCrE was found in 38% of the CKD patients. A lower glomerular filtration rate was strongly associated with low UCrE. Self-reported frailty (adjusted odds ratio: 2.19; 95% confidence interval: 1.28-3.77) and the individual components were associated with low UCrE, independent of comorbidities. The frailty-associated variables hemoglobin and albumin were inversely associated with low UCrE, and parathyroid hormone was positively associated with low UCrE.
discussion
Lower kidney function is a strong correlate of low UCrE, and self-reported frailty, and the individual frailty components are associated with low UCrE as well, independent of comorbidities.
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease INTROduCTION
Urinary creatinine excretion (UCrE), measured by 24-hour urine sampling, is an estab-lished marker of muscle mass in individuals at steady state. 1-7 Low UCrE has been
recog-nized as a predictor of mortality and adverse health outcomes in patients with stage 3 to 5 chronic kidney disease (CKD) 3-5 and various other populations. 7-13 However, the link
between low muscle mass and adverse health outcomes remains unclear. Explanations include that low UCrE reflects worse muscle health, or is related to chronic low-grade inflammation, insulin resistance, or protein caloric malnutrition. We hypothesize that frailty is related to low UCrE, because low muscle mass is an important component of frailty, and especially of the physical frailty definition. 14 Frailty is common in patients
with advanced CKD and has been associated with earlier need for dialysis initiation, lower quality of life, and increased mortality risk. 15-20 CKD has been hypothesized as an
accelerator of decline of physical function that leads to frailty. 21-23 However, whether
frailty is associated with a low UCrE in advanced CKD has not yet been studied. Further-more, reference values of UCrE are lacking. Therefore, we first aimed to determine low UCrE by using the UCrE distribution of a healthy population and subsequently evalu-ate correlevalu-ates of low UCrE. Second, we aimed to evaluevalu-ate associations of self-reported frailty, the individual components that define self-reported frailty, and frailty-associated variables with low UCrE in a cohort of patients with advanced CKD.
METHOdS
Study design and Population
To define low UCrE values, we included as healthy population a subsample representative for the general population (n=3432) of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study. This prospective, population-based cohort study investigates the natural course of urinary albumin excretion and its relation with renal and cardio-vascular disease. Detailed information on the design of the PREVEND study has been published previously. 24 In summary, all inhabitants of the city of Groningen aged 28–75
years were sent a questionnaire and a vial to collect a first-morning-void urine sample. We excluded pregnant women and subjects with diabetes mellitus type 1 from the 40,856 respondents, and 2 cohorts were formed based on urinary albumin concentration. From these 2 cohorts, a subsample of 3432 subjects was derived that was representative of the general population. From this subsample, we excluded participants with no UCrE available, no serum creatinine and/or height available, those with comorbid conditions, or those aged younger than 25 years, which left 2892 participants for the present study.
Participants with missing UCrE values did not differ significantly from participants for whom UCrE values were available. The PREVEND study was approved by the institutional review board and all participants gave written informed consent.
The CKD population included participants of the multicenter observational Predialysis Patients Records-study (PREPARE-2) and Netherlands Cooperative Study on the Ad-equacy of Dialysis (NECOSAD) studies. PREPARE-2 included 502 patients with CKD stage 4 aged 18 years or older who were treated by a nephrologist and had recently been referred to a specialized predialysis outpatient clinic. All patients had to be suitable for renal replacement therapy. Patients with chronic transplant dysfunction were excluded from the study if the transplant was within the previous year. NECOSAD included 2051 dialysis-initiating patients with CKD stage 5. To be eligible for inclusion in NECOSAD, adult patients (age 18 years or older) had to start with dialysis as their first renal replace-ment therapy. No other inclusion or exclusion criteria were applied. The institutional re-view boards of all participating hospitals approved the studies. All patients gave written informed consent. Detailed information on the design of the PREPARE-2 and NECOSAD studies has been published previously. 25, 26
For this present study we included 340 and 1055 participants of PREPARE-2 and NECOSAD respectively, aged between 25 years or older and 85 years and younger, for whom height and UCrE were available, and UCrE was collected before dialysis initia-tion (NECOSAD). In PREPARE-2, patients with missing UCrE values had a higher median estimated glomerulofiltration rate (eGFR), according to the Modification of Diet in Renal Disease Study equation, compared with patients for whom UCrE values were available (16.2 ml/min/1.73m2 vs. 13.9 ml/min/1.73m2, respectively; P=0.03), a lower median
albu-min (39 g/L vs. 42 g/L, respectively; P<0.001), and were less likely to have low physical performance (53% vs. 65%; P=0.03). In NECOSAD, patients with missing UCrE values were slightly older (median age 64.4 years vs. 61.9 years; P=0.004), had lower hemoglobin values (median 6.3 mmol/L vs. 6.4 mmol/L, P=0.02), higher eGFR Modification of Diet in Renal Disease Study equation values (median 7.0 ml/min/1.73m2 vs. 6.7 ml/min/1.73m2; P=0.02), and lower albumin values (median 35 g/L vs. 37 g/L; P<0.001).
Frailty
Self-reported frailty was defined similar to a frequently used modification of Fried’s criteria for frailty developed by Woods et al. 27 and Johansen et al. 28-31 Physical
weak-ness and slowweak-ness was defined as a score <75 on the physical functioning scale of the Short Form of Health Survey-36. Exhaustion was defined as a score <55 on the vitality scale of the Short Form of Health Survey-36. A body mass index (BMI) <18.5 kg/m2 was
used as a substitute for unintentional weight loss. 19 Because underweight is a more
ac-curate description of this modified criterion, the unintentional weight loss criterion is used as “underweight” hereafter. Physical inactivity was defined as the combination of
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease
self-reported moderate or extreme walking problems, with moderate or extreme usual activities limitations according the EuroQol 5-dimensional (EQ-5D) questionnaire.32 A
total of 5 points was possible, with 2 points for low physical functioning and 1 point for each of the other criteria. Patients scoring ≥3 were defined as frail according to the literature.14, 27, 30 For NECOSAD patients, the Short Form of Healthy Survey-36 and
EQ-5D questionnaire had to be completed before dialysis initiation or within 7 days from the start of dialysis. In an additional analysis, we studied the association of pre-frailty (a self-reported frailty score of 1 or 2) with low UCrE. Patients in whom all frailty data were available were slightly different from those patients in whom not all frailty data were available. Therefore, patients in whom frailty was available had higher mean levels of UCrE (9.6 mmol/24 hours vs. 8.4 mmol/24 hours; P<0.001), a higher BMI (26.4 kg/m2 vs.
25.2 kg/m2; P<0.001), and higher levels of GFR (12.5 ml/min vs. 9.5 ml/min; P<0.001),
he-moglobin (7.5 mmol/L vs. 6.6 mmol/L, P<0.001), and albumin (40 g/L vs. 37 g/L, P<0.001). Frailty-Associated variables
Frailty-associated variables included cigarette smoking, albumin, parathyroid hormone, hemoglobin, protein-energy wasting according to the Subjective Global Assessment total score, and the Charlson Comorbidity Index. The Charlson Comorbidity Index was divided into 3 tertiles; 1: 0 to 2; 2: 3 to 5; 3: 6 to 10.
laboratory and Other Measurements
Standard laboratory techniques were used in the different centers participating in the PREPARE-2, NECOSAD, and PREVEND study. GFR was calculated as the mean of urea and creatinine clearance, measured from 24-hour urine collections. The abbreviated Modifi-cation of Diet in Renal Disease Study equation was used to measure eGFR.
Educational levels were categorized according to the International Standard Classifi-cation of EduClassifi-cation as bachelor, master or doctorate graduate (level 1), postsecondary or nontertiary or short-cycle tertiary education (level 2), upper secondary education (level 3), lower secondary education (level 4), and primary or less than primary educa-tion (level 5).33 Malignancy (n=82) was defined as a history of (83%), or active (treated or
untreated) malignancy (17%). The skin tumors squamous cell carcinoma and basal cell carcinoma were excluded for the definition of malignancy.
Statistical Analyses
Differences between patients with low UCrE versus normal range UCrE were tested for statistical significance using Student’s t-test, Mann-Whitney test, or χ2 test, as appropriate.
Low UCrE was defined stratified by sex, then indexed by height (UCrE/height); we subsequently calculated the 5th and 95th percentiles per 5-year age category. These values were plotted, and a third order polynomial regression line was chosen, because
this model yielded the highest R2 values. UCrE was indexed by height, because muscle
mass is highly dependent on body size. All height-indexed UCrE values in patients with CKD that were below the 5th percentile of the healthy population were defined as low.
Logistic regression was used to identify correlates of low UCrE, presented in (i) crude analyses; (ii) analyses adjusted for age, race, sex, and height; and (iii) analyses with all variables added in 1 model. Furthermore, logistic regression was used to evaluate the as-sociations of the frailty variables with low UCrE. These models are presented as (i) crude, and then adjusted for (ii) comorbidities, and (iii) GFR, using both the linear and quadratic form of GFR to allow for nonlinear associations. Adjustment for GFR was performed to model the effect of kidney function on both frailty and low UCrE. A subsidiary multivari-ate linear regression analysis was performed with UCrE tremultivari-ated as a continuous variable.
Subjects with UCrE values that were biologically implausible (UCrE <3.09 or >30.9 mmol/day) were excluded.34 Furthermore, patients with the 5% greatest differences
between measured UCrE and calculated UCrE were excluded. For this purpose, we calculated the estimated UCrE by multiplying creatinine clearance (according to the Cockroft-Gault formula) with plasma creatinine.
Missing values of variables that were used for adjustment were imputed with stan-dard multiple imputation techniques using 10 repetitions. Information on chronic lung disease and malignancy was missing in 31% of cases due to availability in the NECOSAD study only. Information on urea clearance was missing in 42% of cases. The multiple imputation model included the characteristics described in Table 1.
Several sensitivity analyses were performed. First, we repeated the analyses without excluding subjects with UCrE values <3.09 or >30.9 mmol/day. Second, we repeated the analyses in complete cases. Third, we tested potential interactions of the frailty variables with the original study cohort. Subsequently, we repeated the analyses in the PREPARE-2 and NECOSAD cohorts separately.
A P value <0.05 was considered statistically significant. All analyses were performed in SPSS (version 22.0; IBM, Armonk, New York).
RESulTS
Study Participants
The healthy control group included 2748 PREVEND participants, after excluding subjects with UCrE values that were biologically implausible (UCrE <3.09 or >30.9 mmol/day) and excluding patients with the 5% highest differences between measured UCrE and calculated UCrE. The CKD population finally included 320 PREPARE-2 and 967 NECOSAD participants, after applying the same exclusion methods as the healthy cohort to
ex-Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease
clude possibly incorrectly measured UCrE values. Patient characteristics according to study population are shown in Supplementary Table 1.
Table 1 Patient characteristics according urinary creatinine excretion level
All CKD patients Low UCrE Normal UCrE
N=1287 38% 62%
UCrE – men (mmol/24h) 9.4 (7.6-11.4) 7.5 (6.3-8.5) 11.0 (9.7-12.4) a
UCrE – women 6.9 (5.7-8.4) 5.2 (4.7-6.1) 8.0 (6.8-9.2) a
Demographics
Age (yr) 63.1 (51.9-72.4) 62.5 (51.6-70.4) 64.2 (52-74.1) b
Men (%) 63 67 60 c
Non-caucasian race (%) 8 9 7 Primary kidney disease (%)
Glomerulonephritis 13 10 15 Diabetes Mellitus 15 18 14 Renal vascular disease 19 18 18
Other 53 53 53 Educational level (%) Level 1 5 5 6 Level 2 9 9 9 Level 3 18 19 17 Level 4 42 43 42 Level 5 26 25 26 Smoking (%) 27 32 24 b Anthropometry
Body mass index (kg/m2) 24.8 (22.5-27.9) 23.6 (21.5-26.1) 25.7 (23.3-28.7) a
Length (cm) 171.3 (±9.7) 171.4 (±9.3) 171.3 (±9.9) Weight (kg) 74.0 (65-84) 70.7 (62-79) 76.9 (67-87) a Comorbidities (%) Myocardial infarction 13 15 12 Heart failure 12 15 10 c DM 23 26 22
Peripheral vascular disease 16 18 14
CVA 10 9 9
Malignancy 9 10 9
Chronic lung disease 7 9 6 Charlson Comorbidity Index
Class 1 32 34 33 Class 2 32 30 32 Class 3 36 36 35 Laboratory results eGFR (ml/min/1.73m2) 8.0 (5.8-11.4) 7.1 (5.5-10.0) 8.3 (6.1-12.5) a GFR (ml/min) 9.5 (7.3-12.3) 7.4 (5.6-9.2) 11.2 (8.9-14.0) a Hemoglobin (mmol/L) 6.8 (±1.1) 6.5 (±1.1) 7.0 (±1.2) a Albumin (g/L) 38 (34-42) 36 (31-40) 39 (35-43) a
definition of low uCrE
The regression equation of the 5th percentile of UCrE values was modeled as follows:
UCrE/height (m) 5th percentile =
−0.0338 age3+ 4.8107 age2− 240.54 age + 8462.7)/1000 (women)
(−0.111 age3+ 17.185 age2− 869.31 age + 19,838)/1000 (men)
0 2 4 6 8 10 12 14 25 35 45 55 65 75 85 UC rE (m m ol/ 24 hr ) /h t ( m ) Age (year) Males
Met opmerkingen [HP8]: hierachter graag ergens tabel 1
invoegen The fit of the regression model, and the fits of the other models that were tested are
shown in Supplementary Table 2, and the fit of the regression model is further visualized in Supplementary Figures 1a and 1b. Of the CKD patients, 38% had a low UCrE value according to the 5th percentile of the healthy population (Figures 1a and 1b). Of the patients with low UCrE, 88% originated from the NECOSAD study. Patients with low UCrE had a lower BMI, lower albumin, hemoglobin, and eGFR levels, compared with patients with a normal UCrE (Table 1).
Potential Correlates of low uCrE
Crude odds of low UCrE were significantly higher in men, smokers, patients with heart failure, patients with peripheral vascular disease, and patients with lower GFR (Table 2). Excluding patients with peripheral vascular disease defined as an amputation (n=14) yielded similar results (model 3: odds ratio [OR] 1.88; 95% confidence interval [CI]: 1.13-3.12; P=0.01). Remarkably, patients in the oldest age quintile showed significant lower odds of low UCrE compared with the youngest age quintile (OR: 0.31; 95% CI: 0.17-0.57;
P<0.001). A low GFR was the strongest correlate of low UCrE in model 3. Compared with
patients with glomerulonephritis (GN) as primary cause of renal disease, patients with other primary causes of renal disease (e.g., diabetes mellitus, hypertension) were more likely to have low UCrE.
Self-Reported Frailty and low uCrE
All the individual items of the self-reported frailty definition were available for 353 patients, 56% of whom were categorized as frail. Of the individual frailty components, Table 1 Patient characteristics according urinary creatinine excretion level (continued)
All CKD patients Low UCrE Normal UCrE PTH (pmol/L) 17.8 (10-28.1) 18.3 (8.3-46.9) 16.9 (10.0-27.1) SGA total score (%)
1-5= severe - moderate PEW 9 17 9 6-7= normal nutritional status 91 83 92
CVA, cerebrovascular accident; DM, diabetes mellitus; GFR, glomerular filtration rate; PEW, protein-energy wasting; PTH, parathyroid hormone; SGA, subjective global assessment of nutritional status; UCrE, urinary creatinine excretion. Data are given as mean ±SD or median (interquartile range). Charlson Comorbidity Index: class 3 indicating the highest comorbidity burden. Educational level: level 1= university, level 5= primary school or less. a P<0.001; b P <0.01; c P<0.05, cases versus noncases.
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease 0 2 4 6 8 10 12 14 25 35 45 55 65 75 85 UC rE (m m ol/ 24 hr ) / ht (m ) Age (year) Males 0 2 4 6 8 10 12 14 25 35 45 55 65 75 85 UC rE (m m ol/ 24 hr ) / ht (m ) Age (year) Females 0 2 4 6 8 10 12 14 25 35 45 55 65 75 85 UC rE (m m ol/ 24 hr ) / ht (m ) Age (year) Males 0 2 4 6 8 10 12 14 25 35 45 55 65 75 85 UC rE (m m ol/ 24 hr ) / ht (m ) Age (year) Females
Figure 1 Low urinary creatinine excretion in (a) male and (b) female patients with advanced CKD. Dashed line represents the 95th percentile, and the solid line represents the 5th percentile of urinary creatinine excretion (UCrE) values in a healthy population.
Table 2 Potential correlates of low urinary creatinine excretion
Model 1 Model 2 Model 3
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age (yr) < 48.4 (ref) 48.5 - 59.3 1.26 0.88-1.79 0.21 1.24 0.87-1.77 0.24 1.20 0.73-1.97 0.48 59.4 - 67.35 1.43 1.002-2.03 0.05 1.33 0.93-1.91 0.12 1.40 0.84-2.34 0.20 67.36 - 74.07 1.30 0.91-1.86 0.14 1.23 0.85-1.76 0.27 0.88 0.51-1.51 0.63 ≥ 74.1 0.50 0.34-0.73 <0.001 0.45 0.30-0.67 <0.001 0.31 0.17-0.57 <0.001 Male gender 1.31 1.03-1.66 0.03 1.66 1.21-2.27 0.002 2.07 1.32-3.25 0.002 Race Caucasian (ref) Non-Caucasian 1.24 0.83-1.86 0.30 1.07 0.70-1.64 0.75 0.97 0.52-1.80 0.92 Educational level Level 1
physical inactivity was present in 42%, exhaustion and/or fatigue in 55%, low physical functioning in 66%, and underweight in 3% of the patients.
Self-reported frailty, and all the individual components that define self-reported frailty, were significantly associated with low UCrE (Table 3). Of the individual components, underweight yielded the highest odds of low UCrE (crude OR: 3.75; 95% CI: 1.76-7.98;
P=0.001). Adjustment for comorbidities in model 2 did not change the results. Additional
adjustment for GFR in model 3 attenuated most associations, except for albumin and the individual component underweight. Similar results were obtained when UCrE was mod-eled as a continuous outcome (Supplementary Table 3). An additional analysis showed that prefrailty was associated with low UCrE with similar odds in model 1 and model 2. Table 2 Potential correlates of low urinary creatinine excretion (continued)
Model 1 Model 2 Model 3
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Level 2 0.96 0.53-1.74 0.89 0.80 0.43-1.50 0.48 0.88 0.40-1.93 0.75 Level 3 1.07 0.67-1.73 0.77 0.90 0.54-1.50 0.69 1.06 0.56-2.01 0.86 Level 4 1.17 0.80-1.71 0.41 1.07 0.71-1.61 0.76 1.67 0.98-2.83 0.06 Level 5 1.05 0.77-1.42 0.78 0.95 0.70-1.32 0.77 1.00 0.66-1.51 0.99 Primary kidney disease
Glomerulonephritis (ref) DM 2.16 1.39-3.35 0.001 2.30 1.46-3.62 <0.001 3.02 1.28-7.09 0.01 Renovascular disease 1.58 1.04-2.41 0.03 1.77 1.14-2.75 0.01 2.27 1.22-4.24 0.01 Other 1.56 1.08-2.26 0.02 1.75 1.20-2.55 0.004 1.94 1.18-3.21 0.009 Smoking 1.38 1.06-1.78 0.02 1.33 1.02-1.74 0.04 1.36 0.95-1.96 0.10 GFR (ml/min) quartiles 1st (1.6-5.3) 25.8 16.0-41.8 <0.001 33.2 20.0-55.1 <0.001 41.4 22.5-76.2 <0.001 2nd (5.3-7.2) 6.15 3.95-9.55 <0.001 7.13 4.50-11.3 <0.001 9.03 5.21-15.7 <0.001 3th (7.2-9.6) 2.26 1.36-3.78 0.002 2.29 1.35-3.87 0.002 2.35 1.26-4.38 0.008 4th (9.6-32.4) (ref) Myocardial infarction 1.33 0.94-1.88 0.10 1.29 0.90-1.85 0.17 1.34 0.79-2.29 0.28 Heart failure 1.47 1.04-2.08 0.03 1.63 1.13-2.37 0.009 1.29 0.74-2.25 0.36 DM 1.25 0.95-1.64 0.11 1.28 0.96-1.70 0.09 1.14 0.59-2.21 0.70 Peripheral vascular disease 1.37 1.00-1.87 0.05 1.45 1.04-2.01 0.03 1.73 1.06-2.83 0.03 CVA 0.90 0.61-1.34 0.61 0.90 0.60-1.35 0.61 1.06 0.61-1.85 0.84 Malignancy 1.04 0.67-1.62 0.86 1.09 0.68-1.75 0.72 1.11 0.60-2.07 0.73 Chronic lung disease 1.47 0.85-2.54 0.17 1.48 0.85-2.58 0.17 2.06 1.03-4.14 0.04
CI, confidence interval; CVA, cerebrovascular accident; DM, diabetes mellitus; GFR, glomerular filtration rate; OR, odds ratio.
The dependent variable in the analyses is low urinary creatinine excretion.
Model 1 = crude; Model 2 = adjusted for age, race, sex, and height; Model 3 = all variables added in 1 model. Educational level: level 1 = university, level 5 = primary school or less.
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease
Sensitivity Analyses
First, including subjects with UCrE values <3.09 or >30.9 mmol/day, yielded similar results for the analysis of potential correlates of low UCrE, and for the analysis of self-reported frailty and low UCrE. Second, the results remained essentially similar when repeating the analyses with complete cases. Third, no significant interaction was found between the original study cohort and 1 of the frailty variables. Repeating the analyses in the PREPARE-2 and NECOSAD cohorts separately yielded essentially similar results, but did not reach significance in the NECOSAD cohort due to lower power because the frailty variables were available more often in patients in PREPARE-2 (n=243) than in patients in NECOSAD (n=110) (Supplementary Tables 4-7).
Table 3 Associations of frailty, the individual components, and frailty-associated variables with low uri-nary creatinine excretion
Model 1 Model 2 Model 3
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Frailty (n=353) 2.11 1.25 3.54 0.005 2.19 1.28-3.77 0.005 1.65 0.86-3.15 0.13
Individual frailty components
Poor physical performance (n=364) 1.36 1.04-1.79 0.03 1.35 1.02-1.79 0.04 1.31 0.93-1.84 0.12 Exhaustion/fatigue (n=371) 2.37 1.42-3.96 0.001 2.40 1.41-4.08 0.001 1.79 0.96-3.35 0.07 Underweight (n=1281) 3.75 1.76-7.98 0.001 3.86 1.80-8.28 0.001 4.26 1.74-10.4 0.002 Physical inactivity (n=376) 1.72 1.06-2.78 0.03 1.79 1.08-2.97 0.02 1.42 0.77-2.59 0.26
Frailty associated variables
Hemoglobin (mmol/L) (n=927) 0.70 0.62-0.79 <0.001 0.70 0.62-0.79 <0.001 1.12 0.95-1.31 0.18 Albumin (g/L) (n=1182) 0.92 0.91-0.94 <0.001 0.93 0.91-0.95 <0.001 0.97 0.95-0.998 0.03 PTH (per 10 pmol/L) (n=251) 1.14 1.00-1.29 0.05 1.16 1.02-1.33 0.03 1.04 0.91-1.20 0.57 Charlson comorbidity index (n=905)
Class 1 (ref)
Class 2 1.11 0.80-1.55 0.53 0.99 0.79-1.39 0.94 0.92 0.61-1.37 0.67 Class 3 1.25 0.91-1.71 0.28 0.75 0.47-1.20 0.23 0.64 0.36-1.11 0.11 Moderate-severe PEW (n=260) 2.22 0.90-5.47 0.08 2.22 0.90-5.65 0.10 1.43 0.48-4.28 0.53
CI, confidence interval; OR, odds ratio; PEW, protein-energy wasting according the Subjective Global As-sessment of nutritional status; PTH, parathyroid hormone.
The dependent variable in the analyses is low urinary creatinine excretion.
Model 1 = crude; Model 2 = model 1 + adjusted for heart failure, diabetes mellitus, myocardial infarct, peripheral vascular disease, cerebrovascular accident, malignancy, and chronic lung disease; Model 3 = model 2 + glomerular filtration rate. Charlson Comorbidity Index: class 3 indicating the highest comorbid-ity burden.
dISCuSSION
This study showed that self-reported frailty, all the individual components that define self-reported frailty, and the frailty-associated variables hemoglobin, albumin, and parathyroid hormone were associated with low UCrE, independent of comorbidities. Furthermore, we found that low UCrE is present in more than one-third of patients with advanced CKD, and was strongly related to a lower kidney function level.
To the best of our knowledge this was the first study to investigate the associations of self-reported frailty with low UCrE as a measure of low muscle mass, which showed that self-reported frailty is associated with low UCrE. Although frailty has not been related to low UCrE yet, frailty has been associated with other measures of muscle mass. In a population of older community-dwelling adults, a high calf circumference was associ-ated with a lower level of frailty, better muscle strength and better performance on the Short Physical Performance Battery. 35 Associations of frailty with lower quadriceps
muscle area or with intracellular water as a measure of muscle mass have been reported in the hemodialysis population. 36, 37
Low UCrE was prevalent in 38% of the patients with advanced CKD, and the preva-lence was higher in patients with lower GFR values, which suggested an effect of CKD on muscle mass. This finding was in accordance with 2 previous studies that found lower UCrE per increasing CKD stage, 8 and a decrease in UCrE with declining kidney function
over time, independent of nutritional factors. 38 Furthermore, a lower kidney function
was associated with muscle atrophy, reduced walking speed, and more rapid declines in lower-extremity strength over time. 39 Studies that used other methods to measure
muscle mass found the same association of impaired kidney function and low muscle mass. 7, 21, 40, 41 Low UCrE might be a reflection of not only muscle mass, but also of low
muscle function. Wilson et al. showed a lower creatinine generation rate per kilogram of skeletal muscle mass, measured as fat free mass by bioelectrical impedance analysis in those with lower GFR.7 This lower creatinine generation rate might be explained by
altered muscle metabolism in advanced CKD that leads to lower UCrE and poorer muscle function. This hypothesis was favored by the recent study of Marcus et al., which showed that poor physical function in hemodialysis patients was not explained by low muscle mass or comorbid conditions. 42
Theoretically, an alternative explanation could exist why UCrE is lower in later stage CKD. The lower UCrE could to some extent be explained by an increase in extrarenal clearance of creatinine. 43, 44 Extrarenal clearance of creatinine was investigated in only
2 studies, which included a maximum of 10 patients each and reported a wide range of extrarenal clearance. 45, 46 Most important, they did not measure muscle mass
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease
creatinine and kidney function. Therefore, the degree of extrarenal clearance in relation to impaired kidney function is unknown.
The mechanisms that cause loss of muscle mass in CKD are incompletely understood. Muscle loss occurs either because of increased muscle protein breakdown or decreased muscle protein synthesis or a combination of both. Reduced muscle protein synthesis has been found in CKD.47 Increased muscle protein breakdown is a result of increased
catabolic processes, which can be the result of several CKD-associated conditions like chronic inflammation, uremia, acidosis, decline of insulin-like growth factor 1, alterations in vitamin D, and protein-energy wasting. 22, 48, 49 Low physical activity, which is common
in patients who start dialysis, 50 induces loss of muscle mass as well. However, these
mechanisms that cause loss of muscle mass in CKD are beyond the scope of this present study.
Remarkably, the associations of underweight and albumin with low UCrE were inde-pendent of GFR. Similarly, Tynkevich et al. described a strong association of a BMI <18.5 kg/m2 with low UCrE independently of measured GFR in patients with advanced CKD. 38
These findings suggested a strong direct effect of underweight on muscle mass, not via chronic kidney disease per se, whereas the associations of other physical frailty compo-nents such as poor physical performance, exhaustion, and physical inactivity with low UCrE might be caused by reduced GFR, and the complications of CKD (e.g., metabolic acidosis, inflammation) more directly. Therefore, our hypothesis is that a reduced GFR leads to muscle wasting, both directly, and indirectly via weakness, slowness, physical inactivity and exhaustion. Furthermore, the inflammation and other complications of advanced CKD might also contribute to loss of muscle mass.
Concerning the potential correlates of low UCrE, a remarkably lower risk of a low UCrE in patients with CKD aged 74 years and older was found. This lower risk might be explained by selection bias of a relatively healthier older population that was admitted to initiate dialysis therapy. Nephrologists might have been more cautious to refer elderly CKD patients in a poor physical condition to specialized predialysis outpatient clinics (PREPARE-2) or to initiate dialysis (NECOSAD) when compared with younger CKD patients. Furthermore, a remarkable finding was a higher odds of low UCrE in men compared with women. There are several explanations. First, relatively more frail male patients might have been selected to initiate dialysis therapy compared with female patients. Second, CKD might have a larger impact on muscle mass in male patients compared with female patients. Non-GN causes of renal failure were significantly associated with low UCrE compared to GN. This finding might be explained by a higher comorbidity burden in the non-GN patients (e.g., hypertension, diabetes and cardiovascular diseases) and the fact that these comorbidities would result in a higher prevalence of frailty and low UCrE. 27
This study used a self-reported definition of frailty, which was used in previous studies, except for the definition of low physical activity. 27-31 This self-reported frailty definition
was similar to a frequently used modification of the Fried frailty phenotype, which is based on 5 physical criteria. We modified the definition of low physical activity by us-ing items of the EQ-5D, which yielded a similar percentage of patients beus-ing physically inactive (42%) compared with other (advanced) CKD populations (36-54%). 17-19, 30, 51
Johansen et al. compared physical functioning according to the self-reported frailty defi-nition with gait speed and grip strength in hemodialysis patients. Self-reported frailty identified nearly all patients with objective measured frailty with a sensitivity of 90%. 20
In the sensitivity analysis, we found nonsignificant associations of self-reported frailty and the individual frailty components when NECOSAD was analyzed separately. However, the effect measures were similar in both separate cohorts, and an interaction term of the origi-nal cohort with the several independent frailty variables did not reach significance. There-fore, we argue that the associations of frailty with low UCrE were not cohort-dependent. The strengths of this study include that this was the first study that used a large gen-eral population-based cohort as a control group to define low UCrE values, adjusted for height, age, and sex. Second, this was the first study that evaluated associations of low UCrE with self-reported frailty. UCrE values were available in a large cohort of well-phenotyped patients with advanced CKD. Furthermore, in the absence of measured GFR, we used the mean of creatinine and urea clearance, which is the best estimate of true GFR that is clinically available in patients with advanced renal failure. 52
Our study should be interpreted in the light of several limitations. First, using creati-nine excretion from 24-hr urine collections as a measure of muscle mass might include collection errors. However, in all 3 studies, participants received thorough instructions, and potential invalid collections were excluded. Furthermore, we checked for possible invalid urine collections in sensitivity analyses and found similar results. Second, the GFR values that we used were related to UCrE, because both were calculated from creatinine in 24-hour urinary samples. However, using the mean of urea and creatinine clearance for GFR reduced this effect. Third, the shape of the UCrE reference curve was extrapo-lated in the older age values because the healthy cohort included younger individuals compared with the patients with advanced CKD in this study. Future studies should check whether the UCrE reference curve is still accurate in the elderly patients (i.e., older than75 years) with advanced CKD. Fourth, because of the cross-sectional design, any causal interpretation regarding the direction of the associations between low UCrE and self-reported frailty could be considered only very carefully. Furthermore, low UCrE was defined in a mainly Caucasian population, which limited generalizability. In contrast, this homogeneity of race might have led to elimination of potential complicating factors when deriving thresholds for low UCrE, making the data easier to understand. Finally, we used the EQ-5D as a substitute for the frailty criterion of physical inactivity and thereby presumed physical inactivity to be present indirectly based on patients’ report of physi-cal disability and/or limitation. However, because the Minnesota Leisure Time Activity
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease
questionnaire, which was used by Fried et al. to define the physical inactivity criterion, is frequently not available in large cohorts, researchers have mostly used other defini-tions. The physical inactivity criterion is probably the most complicated to define and translate. 53
This study provides an equation to define low UCrE values for epidemiological re-search and clinical practice for patients with advanced CKD. Although not commonly used in the United States, collection of 24-hour urine samples is routinely performed in clinical care and is accepted as a valuable procedure to assess kidney function and to estimate dietary compliance to sodium (and protein) restricted diets. In clinical practice, with 24-hour urine samples available, low UCrE might be used to identify patients with frailty and higher risk of adverse health outcomes, in whom interventions could be initi-ated to improve physical performance. Numerous studies demonstriniti-ated that exercise has beneficial effects on physical performance and quality of life in patients with various stages of CKD. 54-57 These studies implied that exercise may reverse certain aspects of
frailty in CKD patients. Whether low UCrE has an association with outcomes (e.g. mortal-ity), independent of BMI and GFR in advanced CKD patients needs to be investigated and is beyond the scope of the present study.
In conclusion, lower kidney function is a strong correlate of low UCrE, and self-reported frailty, and the individual frailty components are associated with low UCrE as well, independent of comorbidities.
ACKNOWlEdGEMENTS
We are grateful to the patients and staff of all the participating hospitals of the NECOSAD, PREPARE-2, and PREVEND studies.
REFERENCES
1. Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S: Measurement of muscle mass in humans: Validity of the 24-hour urinary creatinine method. Am J Clin Nutr 37: 478-494, 1983
2. Proctor DN, O’Brien PC, Atkinson EJ, Nair KS: Comparison of techniques to estimate total body skeletal muscle mass in people of different age groups. Am J Physiol 277: E489-95, 1999 3. Wang ZM, Gallagher D, Nelson ME, Matthews DE, Heymsfield SB: Total-body skeletal muscle mass:
Evaluation of 24-h urinary creatinine excretion by computerized axial tomography. Am J Clin Nutr 63: 863-869, 1996
4. Welle S, Thornton C, Totterman S, Forbes G: Utility of creatinine excretion in body-composition studies of healthy men and women older than 60 y. Am J Clin Nutr 63: 151-156, 1996
5. Keshaviah PR, Nolph KD, Moore HL, Prowant B, Emerson PF, Meyer M, Twardowski ZJ, Khanna R, Ponferrada L, Collins A: Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 4: 1475-1485, 1994
6. Wyss M, & Kaddurah-Daouk R: Creatine and creatinine metabolism. Physiol Rev 80: 1107-1213, 2000
7. Wilson FP, Xie D, Anderson AH, Leonard MB, Reese PP, Delafontaine P, Horwitz E, Kallem R, Navaneethan S, Ojo A, Porter AC, Sondheimer JH, Sweeney HL, Townsend RR, Feldman HI, CRIC Study Investigators: Urinary creatinine excretion, bioelectrical impedance analysis, and clinical outcomes in patients with CKD: The CRIC study. Clin J Am Soc Nephrol 9: 2095-2103, 2014 8. Di Micco L, Quinn RR, Ronksley PE, Bellizzi V, Lewin AM, Cianciaruso B, Ravani P, Alberta Kidney
Disease Network (AKDN): Urine creatinine excretion and clinical outcomes in CKD. Clin J Am Soc Nephrol 8: 1877-1883, 2013
9. Ix JH, de Boer IH, Wassel CL, Criqui MH, Shlipak MG, Whooley MA: Urinary creatinine excretion rate and mortality in persons with coronary artery disease: The heart and soul study. Circulation 121: 1295-1303, 2010
10. Oterdoom LH, Gansevoort RT, Schouten JP, de Jong PE, Gans RO, Bakker SJ: Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. Atherosclerosis 207: 534-540, 2009
11. ter Maaten JM, Damman K, Hillege HL, Bakker SJ, Anker SD, Navis G, Voors AA: Creatinine excre-tion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure. Clin Res Cardiol 103: 976-983, 2014
12. Sinkeler SJ, Kwakernaak AJ, Bakker SJ, Shahinfar S, Esmatjes E, de Zeeuw D, Navis G, Lambers Heerspink HJ: Creatinine excretion rate and mortality in type 2 diabetes and nephropathy. Diabe-tes Care 36: 1489-1494, 2013
13. Tynkevich E, Flamant M, Haymann JP, Metzger M, Thervet E, Boffa JJ, Vrtovsnik F, Houillier P, Frois-sart M, Stengel B, NephroTest Study Group: Urinary creatinine excretion, measured glomerular filtration rate and CKD outcomes. Nephrol Dial Transplant 30: 1386-1394, 2015
14. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56: M146-56, 2001
15. Dalrymple LS, Katz R, Rifkin DE, Siscovick D, Newman AB, Fried LF, Sarnak MJ, Odden MC, Shlipak MG: Kidney function and prevalent and incident frailty. Clin J Am Soc Nephrol 8: 2091-2099, 2013 16. Reese PP, Cappola AR, Shults J, Townsend RR, Gadegbeku CA, Anderson C, Baker JF, Carlow D,
Sulik MJ, Lo JC, Go AS, Ky B, Mariani L, Feldman HI, Leonard MB, CRIC Study Investigators: Physical performance and frailty in chronic kidney disease. Am J Nephrol 38: 307-315, 2013
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease 17. Roshanravan B, Khatri M, Robinson-Cohen C, Levin G, Patel KV, de Boer IH, Seliger S, Ruzinski J,
Himmelfarb J, Kestenbaum B: A prospective study of frailty in nephrology-referred patients with CKD. Am J Kidney Dis 60: 912-921, 2012
18. Shlipak MG, Stehman-Breen C, Fried LF, Song X, Siscovick D, Fried LP, Psaty BM, Newman AB: The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis 43: 861-867, 2004
19. Wilhelm-Leen ER, Hall YN, K Tamura M, Chertow GM: Frailty and chronic kidney disease: The third national health and nutrition evaluation survey. Am J Med 122: 664-71.e2, 2009
20. Johansen KL, Dalrymple LS, Delgado C, Kaysen GA, Kornak J, Grimes B, Chertow GM: Comparison of self-report-based and physical performance-based frailty definitions among patients receiving maintenance hemodialysis. Am J Kidney Dis 64: 600-607, 2014
21. Fried LF, Boudreau R, Lee JS, Chertow G, Kurella-Tamura M, Shlipak MG, Ding J, Sellmeyer D, Tylavsky FA, Simsonick E, Kritchevsky SB, Harris TB, Newman AB, Health, Aging and Body Compo-sition Study: Kidney function as a predictor of loss of lean mass in older adults: Health, aging and body composition study. J Am Geriatr Soc 55: 1578-1584, 2007
22. Wang XH, & Mitch WE: Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol 10: 504-516, 2014
23. Anand S, Johansen KL, Kurella Tamura M: Aging and chronic kidney disease: The impact on physi-cal function and cognition. J Gerontol A Biol Sci Med Sci 69: 315-322, 2014
24. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT, PREVEND Study Group: Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 168: 897-905, 2008
25. Suttorp MM, Hoekstra T, Mittelman M, Ott I, Franssen CF, Dekker FW: Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients. PLoS One 8: e84848, 2013 26. de Jager DJ, Halbesma N, Krediet RT, Boeschoten EW, le Cessie S, Dekker FW, Grootendorst DC,
NECOSAD Study Group: Is the decline of renal function different before and after the start of dialysis? Nephrol Dial Transplant 28: 698-705, 2013
27. Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, Masaki K, Murray A, Newman AB, Women’s Health Initiative: Frailty: Emergence and consequences in women aged 65 and older in the women’s health initiative observational study. J Am Geriatr Soc 53: 1321-1330, 2005 28. Delgado C, Shieh S, Grimes B, Chertow GM, Dalrymple LS, Kaysen GA, Kornak J, Johansen KL:
Association of self-reported frailty with falls and fractures among patients new to dialysis. Am J Nephrol 42: 134-140, 2015
29. Bao Y, Dalrymple L, Chertow GM, Kaysen GA, Johansen KL: Frailty, dialysis initiation, and mortality in end-stage renal disease. Arch Intern Med 172: 1071-1077, 2012
30. Johansen KL, Chertow GM, Jin C, Kutner NG: Significance of frailty among dialysis patients. J Am Soc Nephrol 18: 2960-2967, 2007
31. Johansen KL, Dalrymple LS, Glidden D, Delgado C, Kaysen GA, Grimes B, Chertow GM: Associa-tion of performance-based and self-reported funcAssocia-tion-based definiAssocia-tions of frailty with mortality among patients receiving hemodialysis. Clin J Am Soc Nephrol 11: 626-632, 2016
32. Szende A, Oppe M, Devlin N: EQ-5D value sets: Inventory, comparative review and user guide. Springer, Dordrecht, The Netherlands, 2007,
33. UNESCO institute for statistics: International standard classification of education, ISCED 2011. Paris, France, UNESCO, 2011,
34. Ix JH, Wassel CL, Stevens LA, Beck GJ, Froissart M, Navis G, Rodby R, Torres VE, Zhang YL, Greene T, Levey AS: Equations to estimate creatinine excretion rate: The CKD epidemiology collaboration. Clin J Am Soc Nephrol 6: 184-191, 2011
35. Landi F, Onder G, Russo A, Liperoti R, Tosato M, Martone AM, Capoluongo E, Bernabei R: Calf circumference, frailty and physical performance among older adults living in the community. Clin Nutr 33: 539-544, 2014
36. Delgado C, Doyle JW, Johansen KL: Association of frailty with body composition among patients on hemodialysis. J Ren Nutr 23: 356-362, 2013
37. Johansen KL, Dalrymple LS, Delgado C, Kaysen GA, Kornak J, Grimes B, Chertow GM: Association between body composition and frailty among prevalent hemodialysis patients: A US renal data system special study. J Am Soc Nephrol 25: 381-389, 2014
38. Tynkevich E, Flamant M, Haymann JP, Metzger M, Thervet E, Boffa JJ, Vrtovsnik F, Houillier P, Frois-sart M, Stengel B, NephroTest Study Group: Decrease in urinary creatinine excretion in early stage chronic kidney disease. PLoS One 9: e111949, 2014
39. Roshanravan B, Patel KV, Robinson-Cohen C, de Boer IH, O’Hare AM, Ferrucci L, Himmelfarb J, Kestenbaum B: Creatinine clearance, walking speed, and muscle atrophy: A cohort study. Am J Kidney Dis 2014
40. Foster BJ, Kalkwarf HJ, Shults J, Zemel BS, Wetzsteon RJ, Thayu M, Foerster DL, Leonard MB: As-sociation of chronic kidney disease with muscle deficits in children. J Am Soc Nephrol 22: 377-386, 2011
41. Foley RN, Wang C, Ishani A, Collins AJ, Murray AM: Kidney function and sarcopenia in the united states general population: NHANES III. Am J Nephrol 27: 279-286, 2007
42. Marcus RL, LaStayo PC, Ikizler TA, Wei G, Giri A, Chen X, Morrell G, Painter P, Beddhu S: Low physical function in maintenance hemodialysis patients is independent of muscle mass and comorbidity. J Ren Nutr 25: 371-375, 2015
43. GOLDMAN R: Creatinine excretion in renal failure. Proc Soc Exp Biol Med 85: 446-448, 1954 44. Mitch WE, & Walser M: A proposed mechanism for reduced creatinine excretion in severe chronic
renal failure. Nephron 21: 248-254, 1978
45. Mitch WE, Collier VU, Walser M: Creatinine metabolism in chronic renal failure. Clin Sci (Lond) 58: 327-335, 1980
46. Jones JD, & Burnett PC: Creatinine metabolism in humans with decreased renal function: Creati-nine deficit. Clin Chem 20: 1204-1212, 1974
47. Adey D, Kumar R, McCarthy JT, Nair KS: Reduced synthesis of muscle proteins in chronic renal failure. Am J Physiol Endocrinol Metab 278: E219-25, 2000
48. Fahal IH: Uraemic sarcopenia: Aetiology and implications. Nephrol Dial Transplant 29: 1655-1665, 2014
49. Kim JC, Kalantar-Zadeh K, Kopple JD: Frailty and protein-energy wasting in elderly patients with end stage kidney disease. J Am Soc Nephrol 24: 337-351, 2013
50. Johansen KL, Chertow GM, Kutner NG, Dalrymple LS, Grimes BA, Kaysen GA: Low level of self-reported physical activity in ambulatory patients new to dialysis. Kidney Int 78: 1164-1170, 2010 51. Painter P, & Kuskowski M: A closer look at frailty in ESRD: Getting the measure right. Hemodial Int
17: 41-49, 2013
52. Lubowitz H, Slatopolsky E, Shankel S, Rieselbach RE, Bricker NS: Glomerular filtration rate. deter-mination in patients with chronic renal disease. Jama 199: 252-256, 1967
53. Eckel SP, Bandeen-Roche K, Chaves PH, Fried LP, Louis TA: Surrogate screening models for the low physical activity criterion of frailty. Aging Clin Exp Res 23: 209-216, 2011
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease 54. Smart N, & Steele M: Exercise training in haemodialysis patients: A systematic review and
meta-analysis. Nephrology (Carlton) 16: 626-632, 2011
55. Castaneda C, Gordon PL, Uhlin KL, Levey AS, Kehayias JJ, Dwyer JT, Fielding RA, Roubenoff R, Singh MF: Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 135: 965-976, 2001 56. Castaneda C, Gordon PL, Parker RC, Uhlin KL, Roubenoff R, Levey AS: Resistance training to reduce
the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 43: 607-616, 2004
57. Manfredini F, Mallamaci F, D’Arrigo G, Baggetta R, Bolignano D, Torino C, Lamberti N, Bertoli S, Ciurlino D, Rocca-Rey L, Barilla A, Battaglia Y, Rapana RM, Zuccala A, Bonanno G, Fatuzzo P, Rapisarda F, Rastelli S, Fabrizi F, Messa P, De Paola L, Lombardi L, Cupisti A, Fuiano G, Lucisano G, Summaria C, Felisatti M, Pozzato E, Malagoni AM, Castellino P, Aucella F, ElHafeez SA, Provenzano PF, Tripepi G, Catizone L, Zoccali C: Exercise in patients on dialysis: A multicenter, randomized clinical trial. J Am Soc Nephrol 2016
Chapter 3
SuPPlEMENTAl MATERIAl Figure S1a and S1b.
Description: UCrE/height values of healthy population vs age, with the regression equations of the
5th and 95th percentiles superimposed.
Type: pdf.
Figure S1a. UCrE/height values of healthy population vs age, with the regression equations of the 5th and 95th percentiles superimposed -‐ Males.
Figure S2b. UCrE/height values of healthy population vs age, with the regression equations of the 5th and 95th percentiles superimpose -‐ Females.
R² = 0,626 R² = 0,923 1 3 5 7 9 11 13 25 35 45 55 65 75 85 UC rE (m m oll/24hr ) / ht (m ) Age (year) Healthy males - 95th and 5th percen>le of UCrE/ht R² = 0,853 R² = 0,938 1 3 5 7 9 11 13 25 35 45 55 65 75 85 UC rE (m m oll/24hr ) / ht (m ) Age (year) Healthy females - 95th and 5th percen?le of UCrE/ht
Description: UCrE/height values of healthy population vs age, with the regression equations of the
5th and 95th percentiles superimposed.
Type: pdf.
Figure S1a. UCrE/height values of healthy population vs age, with the regression equations of the 5th and 95th percentiles superimposed -‐ Males.
Figure S2b. UCrE/height values of healthy population vs age, with the regression equations of the 5th and 95th percentiles superimpose -‐ Females.
R² = 0,626 R² = 0,923 1 3 5 7 9 11 13 25 35 45 55 65 75 85 UC rE (m m oll/24hr ) / ht (m ) Age (year) Healthy males - 95th and 5th percen>le of UCrE/ht R² = 0,853 R² = 0,938 1 3 5 7 9 11 13 25 35 45 55 65 75 85 UC rE (m m oll/24hr ) / ht (m ) Age (year) Healthy females - 95th and 5th percen?le of UCrE/ht
Supplementary Figure S1 UCrE/height values of healthy population versus age, with the regression equations of the 5th and 95th percentiles superimposed in males (upper) and females (lower).
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease Supplementary Table S1 Patient characteristics according original study cohort
PREVEND PREPARE-2 NECOSAD
Characteristic N=2748 N=320 N=967 UCrE - men 14.3 (12.5-16.2) 10.8 (8.9-12.7) 9.0 (7.4-10.9) UCrE - women 9.8 (8.6-11.3) 8.0 (6.6-9.2) 6.6 (5.5-8.1) Demographics Age (yr) 46.0 (38.0-56.0) 68.6 (56.5-75.6) 62.0 (50.4-71.1) Gender (male) (%) 42 67 62 Race (%) Caucasian Non-Caucasian 95 5 93 7 91 9 Primary kidney disease (%)
Glomerulonephritis DM
Renal vascular disease Other NA 15 14 28 43 13 15 16 56 Educational level (%) Level 1 Level 2 Level 3 Level 4 Level 5 13 23 26 27 12 3 9 21 42 25 6 9 17 42 26 Smoking (%) 34 24 28 Anthropometry BMI (kg/m2) 25.0 (22.8-27.6) 25.9 (23.5-29.6) 24.5 (22.2-27.3) Length (cm) 172.5 ±9.6 171.8 ±9.3 171.2 ±9.8 Weight (kg) 75.0 (66.0-84.0) 77.7 (68.0-88.9) 73.0 (64.0-82.0) Comorbidities (%) Myocardial infarction NA 13 13 Heart failure NA 12 12 DM NA 26 22
Peripheral vascular disease NA 19 15
CVA NA 14 8
Malignancy NA Not available 9 Chronic lung disease Not available Not available 7 Charlson Comorbidity Index (%)
Class 1 Class 2 Class 3
Not available Not available 3232 36
Laboratory results
eGFR (MDRD, ml/min per 1.73m2) 79.7 (71.5-88.7) 16.2 (12.0-20.0) 6.8 (5.3-8.7)
Hemoglobin (g/dL) Not available 12.3 ±1.4 10.4 ±1.7 Albumin (g/L) 46 (44-47) 42 (39-44) 37 (33-40) PTH (pmol/L) Not available 16.1 (10.0-27.1) 24.5 (11.5-42.0) SGA total score (%)
1-5= severe-moderate PEW 6-7= normal nutritional status
Not available 9 91
Not available
Data are given as mean ±SD or median (IQR). UCrE: urinary creatinine excretion; DM: diabetes mellitus; CVA: cerebrovascular accident; eGFR: estimated glomerular fi ltration rate; PTH: parathyroid hormone; SGA: sub-jective global assessment of nutritional status; PEW: protein-energy wasting. Charlson Comorbidity Index: class 3 indicating the highest comorbidity burden. Educational level: level 1= university, level 5= primary
Supplementary Table S2 Fit of the third-order polynomial regression model and fits of the other tested models
R squared
Model Male Female
5th perc. 95th perc. 5th perc. 95th perc.
3rd order polynomial 0.626 0.923 0.853 0.938 Linear 0.379 0.840 0.877 0.796 Power 0.385 0.779 0.791 0.732 Exponential 0.375 0.831 0.865 0.748 Logarithmic 0.394 0.796 0.809 0.751 2nd order polynomial 0.381 0.869 0.824 0.936
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease Supplemen tar y Table S3 Linear reg ression models of the associa tions of self-r epor ted fr ailt y and the individual componen ts , and fr ailt y-associa ted var iables with ur inar y cr ea tinine e xcr etion (c on tinuously) M odel 1 M odel 2 M odel 3 B (S tand B)* 95%CI P B (S tand B)* 95%CI P B (S tand B)* 95% CI P Self-r epor ted fr ailt y -0.92 -1.43; -0.41 <0.001 -0.97 -1.50 t o -0.44 <0.001 -0.35 -0.77 t o 0.07 0.10 Individu al c omp
onents that define fr
ailt y Poor ph ysical per for manc e -0.42 -0.69; t o -0.16 0.002 -0.42 -0.69 t o -0.15 0.002 -0.18 -0.39 t o 0.03 0.10 Exhaustion/fa tigue -0.79 -1.28 t o -0.29 0.002 -0.81 -1.31 t o -0.30 0.002 -0.29 -0.69; 0.11 0.15 Under w eigh t -2.23 -3.07 t o -1.39 <0.001 -2.21 -3.05 t o -1.37 <0.001 -1.82 -2.43 t o -1.21 <0.001 Ph ysical inac tivit y -0.46 -0.96 t o 0.04 0.07 -0.49 -1.00 t o 0.03 0.06 -0.02 -0.43 t o 0.38 0.91 Fr ailt y-asso ciat ed v ariables Hemoglobin (g/dL) 0.28 (0.18) 0.20 t o 0.37 <0.001 0.29 (0.19) 0.21 t o 0.37 <0.001 -0.15 (-0.09)-0.22 t o -0.08 <0.001 A lbumin (g/L) 0.09 (0.19) 0.06 t o 0.11 <0.001 0.09 (0.18) 0.06 t o 0.11 <0.001 0.000 (0.002) -0.02 t o 0.02 0.97 PTH (pmol/L) -0.02 (-0.13) -0.03 t o-0.005 0.008 -0.02 (-0.14) -0.03 t o -0.005 0.007 0.004 (0.03) -0.007 t o 0.01 0.52 Char lson C omor bidit y I nde x Class 1 (r ef ) Class 2 Class 3 -0.23 -0.64 -0.69 t o 0.24 -1.18 t o -0.11 0.34 0.02 -0.19 -0.48 -0.70 t o 0.31 -1.24 t o 0.28 0.45 0.22 -0.34 -0.72 -0.70 t o 0.03 -1.27 t o -0.18 0.07 0.01 M oder at e PE W -0.72 -1.70 t o 0.27 0.15 -0.74 -1.72 t o 0.25 0.15 -0.15 -0.94 t o 0.64 0.72 The dependen t v ar iable in the analy ses is lo w ur inar y cr ea tinine ex cr etion. M odel 1= adjust ed for age , gender , heigh t, rac e; M odel 2= model 1 + adjust ed for hear t failur e, DM, m yocar dial infar ct , per ipher al vascular disease , C VA, malig nanc y, chr onic lung disease; M odel 3= model 2 + GFR. *S tand B: standar diz ed beta not ed for con tinuous var iables only . PTH: par ath yr oid hor mone; PE W : pr ot ein-ener gy w asting ac cor ding the Subjec tiv e Global A ssessmen t of nutr itional sta tus . Char lson Comor bidit y Inde x: class 3 indica
ting the highest c
omor
bidit
y bur
Supplementary Table S4 Sensitivity analysis: PREPARE-2 only: potential correlates of low urinary creati-nine excretion
Model 1 Model 2 Model 3 OR 95%CI P OR 95%CI P OR 95%CI P
Age (yr) < 48.4 (ref) 48.5 - 59.3 59.4 - 67.35 67.36 - 74.07 ≥ 74.1 0.84 2.27 1.74 0.61 0.26-2.71 0.86-6.03 0.66-4.61 0.22-1.72 0.76 0.10 0.26 0.35 0.84 2.16 1.70 0.58 0.26-2.73 0.79-5.93 0.64-4.55 0.20-1.71 0.77 0.13 0.29 0.32 1.62 4.85 2.68 0.27 0.22-11.8 0.89-26.5 0.49-14.6 0.04-1.79 0.63 0.07 0.25 0.18 Male gender 0.95 0.52-1.72 0.85 1.12 0.49-2.60 0.78 2.67 0.72-9.91 0.14 Race Caucasian (ref) Non-Caucasian 1.07 0.35- 3.30 0.91 1.07 0.70-1.64 0.75 1.98 0.25-15.5 0.51 Educational level Level 1 Level 2 Level 3 Level 4 Level 5 (ref) 0 0.96 1.69 0.88 0 0.28-3.38 0.69-4.11 0.38-2.02 0.99 0.95 0.25 0.76 0 0.74 1.53 0.79 0 0.19-2.91 0.59-3.98 0.33-1.91 0.99 0.66 0.38 0.60 0 0.86 1.55 0.63 0 0.11-6.55 0.43-5.57 0.20-2.03 1 0.89 0.51 0.44 Primary kidney disease
Glomerulonephritis (ref)
DM 2.77 0.88-8.71 0.08 2.91 0.89-9.49 0.08 8.20 0.84-79.7 0.07 Renal vascular disease 1.93 0.66-5.63 0.23 1.95 0.65-5.87 0.24 2.01 0.38-10.8 0.41 Other 2.08 0.75-5.76 0.16 2.16 0.75-6.19 0.15 3.93 0.85-18.1 0.08 Smoking 1.13 0.59-2.16 0.72 1.19 0.61-2.34 0.62 1.35 0.46-3.99 0.59 GFR (ml/min) quartiles 1st (5.2-10.3) 36.8 4.81-281 0.001 48.5 5.98-393 <0.001 92.4 8.56-997 <0.001 2nd (10.5-13.5) 19.5 2.53-150 0.004 25.6 3.12-209 0.003 36.5 3.30-405 0.003 3th (13.6-17.7) 3.79 0.35-41.6 0.27 4.38 0.38-50.0 0.23 6.35 0.47-85.2 0.16 4th (17.73-32.4) (ref) Myocardial infarction 0.95 0.40-2.27 0.91 0.93 0.38-2.30 0.88 0.79 0.20-3.05 0.73 Heart failure 1.24 0.54-2.86 0.62 1.53 0.62-3.78 0.35 6.04 1.30-28.1 0.02 DM 1.16 0.61-2.21 0.65 1.20 0.61-2.36 0.60 0.63 0.15-2.70 0.53 Peripheral vascular disease 2.48 1.31-4.70 0.005 3.17 1.58-6.33 0.001 2.94 1.00-8.64 0.05 CVA 1.19 0.54-2.64 0.67 1.26 0.55-2.88 0.59 1.02 0.27-3.82 0.98 Malignancy 1.01 0.24-4.33 0.99 1.06 0.21-5.33 0.94 1.25 0.07-22.1 0.87 Chronic lung disease 0.56 0.06-5.59 0.61 0.55 0.05-5.54 0.60 0.83 0.05-14.6 0.90
The dependent variable in the analyses is low UCrE. Model 1= crude; Model 2 = adjusted for age, race, gender and height; Model 3= all variables in 1 model. DM: diabetes mellitus; GFR: glomerular filtration rate; CVA: cerebrovascular accident; Educational level: level 1= university, level 5 = primary school or below.
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease Supplementary Table S5 Sensitivity analysis: NECOSAD only: potential correlates of low urinary creati-nine excretion
Model 1 Model 2 Model 3 OR 95%CI P OR 95%CI P OR 95%CI P
Age (yr) < 48.4 (ref) 48.5 - 59.3 59.4 - 67.35 67.36 - 74.07 ≥ 74.1 1.33 1.43 1.43 0.61 0.91-1.95 0.97-2.12 0.96-2.13 0.39-0.94 0.14 0.07 0.08 0.03 1.30 1.37 1.35 0.57 0.88-1.92 0.91-2.04 0.90-2.04 0.36-0.90 0.18 0.13 0.15 0.02 1.14 1.17 0.69 0.26 0.66-1.95 0.66-2.06 0.37-1.26 0.13-0.52 0.64 0.59 0.22 <0.001 Male gender 1.49 1.14-1.94 0.003 1.78 1.26-2.52 0.001 2.48 1.51-4.08 <0.001 Race Caucasian (ref) Non-Caucasian 1.20 0.77- 1.88 0.43 1.07 0.70-1.64 0.75 0.92 0.46-1.84 0.81 Educational level Level 1 Level 2 Level 3 Level 4 Level 5 (ref) 1.00 1.12 1.14 1.09 0.53-1.88 0.66-1.91 0.75-1.75 0.77-1.54 0.99 0.67 0.54 0.61 0.90 1.00 1.09 1.06 0.46-1.77 0.57-1.77 0.68-1.75 0.73-1.52 0.77 0.99 0.72 0.77 1.06 1.11 1.51 1.06 0.45-2.49 0.54-2.27 0.82-2.77 0.67-1.68 0.90 0.79 0.19 0.82 Primary kidney disease
Glomerulonephritis (ref)
DM 2.05 1.25-3.36 0.004 2.15 1.29-3.58 0.003 2.92 1.05-8.09 0.04 Renal vascular disease 1.81 1.12-2.95 0.02 1.92 1.15-3.20 0.01 2.68 1.31-5.48 0.007 Other 1.37 0.91-2.06 0.13 1.54 1.01-2.34 0.04 1.98 1.14-3.44 0.02 Smoking 1.39 1.04-1.86 0.03 1.37 1.01-1.85 0.04 1.39 0.94-2.07 0.10 GFR (ml/min) quartiles 1st (1.8-7.2) 35.6 12.7-100 <0.001 59.0 20.7-168 <0.001 130 28.1-599 <0.001 2nd (7.3-9.5) 8.35 3.12-22.3 <0.001 12.1 4.42-33.0 <0.001 26.1 6.20-110 <0.001 3th (9.5-12.3) 2.96 1.01-8.67 0.05 3.51 1.20-10.3 0.02 6.09 1.31-28.2 0.02 4th (12.3-32.4) (ref) Myocardial infarction 1.44 0.97-2.14 0.07 1.33 0.88-2.02 0.18 1.67 0.89-3.12 0.11 Heart failure 1.52 1.05-2.34 0.03 1.57 1.03-2.40 0.04 1.15 0.61-2.16 0.67 DM 1.39 1.02-1.91 0.04 1.40 1.01-1.94 0.04 1.41 0.63-3.14 0.41 Peripheral vascular disease 1.31 0.90-1.89 0.16 1.25 0.85-1.83 0.27 1.31 0.73-2.34 0.36 CVA 1.00 0.62-1.61 0.99 0.94 0.57-1.54 0.80 0.89 0.46-1.72 0.72 Malignancy 0.99 0.62-1.58 0.97 1.03 0.61-1.72 0.92 1.14 0.61-2.13 0.68 Chronic lung disease 1.70 1.00-2.87 0.05 1.69 0.96-2.98 0.07 2.76 1.29-5.91 0.009
The dependent variable in the analyses is low UCrE. Model 1= crude; Model 2 = adjusted for age, race, gen-der and height; Model 3= all variables in 1 model. Educational level: level 1= university, level 5 = primary school or below; DM: diabetes mellitus; GFR: glomerular filtration rate; CVA: cerebrovascular accident.
Supplementary Table S6 Sensitivity analysis: PREPARE-2 only: associations of self-reported frailty and the individual components, and frailty-associated variables with low urinary creatinine excretion
Model 1 Model 2 Model 3 OR 95%CI P OR 95%CI P OR 95% CI P
Self-reported frailty (n=243) 2.72 1.30-5.74 0.008 2.56 1.15-5.66 0.02 1.81 0.72-4.55 0.21
Individual frailty components
Poor physical performance (n=252) 1.49 1.003-2.21 0.05 1.36 0.90-2.06 0.14 1.28 0.79-2.08 0.32 Exhaustion/fatigue (n=258) 2.16 1.10-4.26 0.03 2.10 1.02-4.30 0.04 2.11 0.92-4.87 0.08 Underweight (n=315) 9.44 1.69-52.9 0.01 11.5 1.97-66.6 0.007 16.4 1.86-145 0.01 Physical inactivity (n=260) 1.92 0.99-3.73 0.05 1.81 0.89-3.66 0.10 1.10 0.48-2.53 0.83 Frailty-associated variables Hemoglobin (g/dL) (n=298) 0.76 0.61-0.96 0.02 0.75 0.59-0.96 0.02 0.92 0.70-1.21 0.56 Albumin (g/L) (n=284) 0.95 0.89-1.02 0.15 0.96 0.89-1.03 0.26 1.00 0.92-1.09 1.00 PTH (per 10 pmol/L) (n=225) 1.11 0.97-1.27 0.13 1.14 0.99-1.32 0.08 1.01 0.87-1.19 0.87 Charlson comorbidity index (n=0) * * *
Moderate - severe PEW (n=260) 2.22 0.90-5.47 0.08 2.22 0.87-5.65 0.10 1.43 0.48-4.28 0.53
The dependent variable in the analyses is low urinary creatinine excretion. Model 1= crude; Model 2= model 1 + adjusted for heart failure, DM, myocardial infarct, peripheral vascular disease, CVA, malignancy, chronic lung disease; Model 3= model 2 + GFR. PTH: parathyroid hormone; PEW: protein-energy wasting according the Subjective Global Assessment of nutritional status. Charlson Comorbidity Index: Class 3 indi-cating the highest comorbidity burden. * Too few or no cases for the analysis.
Low urinary Creatinine Excretion is associated with Self-Reported Frailty in Patients with Advanced Chronic Kidney Disease Supplementary Table S7 Sensitivity analysis: NECOSAD only: associations of self-reported frailty and the individual components, and frailty-associated variables with low urinary creatinine excretion
Model 1 Model 2 Model 3 OR 95%CI P OR 95%CI P OR 95% CI P
Self-reported frailty (n=110) 1.43 0.65-3.14 0.38 1.46 0.65-3.31 0.36 1.42 0.48-4.24 0.53
Individual frailty components
Poor physical performance (n=112) 1.24 0.82-1.87 0.31 1.24 0.81-1.91 0.32 1.30 0.74-2.30 0.36 Exhaustion/fatigue (n=113) 2.05 0.89-4.72 0.09 2.24 0.94-5.35 0.07 2.04 0.67-12.4 0.25 Underweight (n=966) 2.93 1.26-6.82 0.01 2.89 1.23-6.78 0.02 3.03 1.12-8.15 0.03 Physical inactivity (n=116) 1.66 0.78-3.53 0.19 1.62 0.71-3.66 0.25 1.79 0.62-5.20 0.28 Frailty-associated variables Hemoglobin (g/dL) (n=629) 0.95 0.87-1.05 0.31 0.95 0.87-1.03 0.30 1.04 0.93-1.17 0.49 Albumin (g/L) (n=898) 0.94 0.92-0.97 <0.001 0.95 0.93-0.97 <0.001 0.96 0.93-0.99 0.002 PTH (per 10 pmol/L) (n=26) 1.30 0.94-1.81 0.12 * *
Charlson comorbidity index (n=905) Class 1 (ref) Class 2 Class 3 1.11 1.25 0.80-1.55 0.91-1.71 0.53 0.18 0.99 0.75 0.70-1.39 0.47-1.20 0.94 0.23 0.92 0.64 0.61-1.37 0.36-1.10 0.67 0.11 Moderate - severe PEW (n=0) * * *
The dependent variable in the analyses is low urinary creatinine excretion. Model 1= crude; Model 2= model 1 + adjusted for heart failure, DM, myocardial infarct, peripheral vascular disease, CVA, malignancy, chronic lung disease; Model 3= model 2 + GFR. PTH: parathyroid hormone; PEW: protein-energy wasting according the Subjective Global Assessment of nutritional status. Charlson Comorbidity Index: Class 3 in-dicating the highest comorbidity burden. * Too few or no cases for the analysis.
